10 stories mentioning QGENUpdated 16d ago
Every FINWIRES story that references QGEN, newest first.
QIAGEN (QGEN) has an average rating of overweight and mean price target of $42.89, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5%, and Ionis tumbled 23%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped 10%.Fate Therapeutics (FATE) shares rose past 5% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.MetaVia (MTVA) shares climbed 11% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5.4%, and Ionis tumbled 24%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped past 10%.MetaVia (MTVA) shares rose 9% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.
Qiagen (QGEN) is attracting early takeover interest from private equity firms including EQT (EQT), Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported Thursday, citing people familiar with the situation.Qiagen, which has been conducting a strategic review with advisers, could also draw interest from additional buyout firms and strategic acquirers. Deliberations are ongoing and there is no certainty they will result in a transaction, according to the report.Qiagen shares rose as much as 14% in US trading before trimming gains to trade up about 11%, valuing the company at roughly $8.7 billion, the report said.Qiagen, EQT, Advent and KKR did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $42.68, Change: $+4.68, Percent Change: +12.32%
Qiagen Attracts Early Takeover Interest From EQT, Advent, KKR, Bloomberg Reports
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price of USD36, implying a 2026 P/E of 14.7x. This is at a discount to its historical average (20x-22x) to reflect the headwinds on its key growth contributor QuantiFERON, along with increased geopolitical and management uncertainties. This is partly cushioned by growth opportunities from other key products and improving shareholder returns. Qiagen published its full Q1 2026 results, which were in line with the preliminary results released in April. Q1 2026 net sales fell 1% CER dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. In April, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50, and expect stronger trends in H2 supported by acquisition benefits and sequential QuantiFERON improvement. Our EPS estimates remained unchanged given the full Q1 results were in line with the preliminary figures.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to USD36 from USD54, and we trim our EPS estimates to USD2.45 from USD2.53 for 2026 and to USD2.64 from USD2.74 for 2027 in light of the guidance cut. The target price implies a 2026 P/E of 14.7x, below its historical average of 20x-22x to reflect headwinds on its key growth contributor QuantiFERON. Qiagen's preliminary Q1 2026 net sales fell 1% CER, missing the company's outlook for at least 1% growth, dragged by QuantiFERON (-5% CER) due to reduced immigration testing demand in the U.S. and Middle East. Given the slow start to the year, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50. We view the sales miss and lowered outlook as disappointing. We still see QuantiFERON as a main growth contributor over the long term, thus monitoring progress in other patient testing groups remains key. Full Q1 results are scheduled for May 6, 2026.
QIAGEN (QGEN) has an average rating of overweight and mean price target of $47.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Qiagen's preliminary Q1 2026 net sales fell by 1% CER, missing the company's outlook for at least 1% growth, while reported sales grew 2% to USD492M, below consensus' USD501M. Preliminary adjusted EPS of USD0.54 was in line with the outlook, though overall results were dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. The company downgraded 2026 guidance to 1%-2% CER sales growth (from at least 5% previously) and adjusted EPS to at least USD2.43 CER (from USD2.50 previously), expecting stronger trends in 2H, supported by acquisition benefits and sequential QuantiFERON improvement. We view the sales miss and lowered outlook as disappointing, but still see QuantiFERON as a main growth contributor, while the Parse acquisition should strengthen Qiagen's competitive position. That said, monitoring progress in other patient testing groups for QuantiFERON remains key. Full Q1 results are scheduled for May 6, 2026.
QIAGEN (QGEN) has an average rating of overweight and mean price target of $54.01, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
